Adding Lestaurtinib to Standard Chemo Produces No Overall Benefit in AML

Share this content:
The addition of lestaurtinib to first-line standard chemotherapy produced no overall clinical benefit.
The addition of lestaurtinib to first-line standard chemotherapy produced no overall clinical benefit.

The addition of lestaurtinib to first-line standard chemotherapy produced no overall clinical benefit among patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML), according to a study published in Blood.1

Lestaurtinib is a tyrosine kinase inhibitor of FLT3, JAK2, TrkA, TrkB, and TrkC. Because the clinical benefit of adding FLT3-directed small molecule therapy to standard frontline chemotherapy in AML has not been established, researchers evaluated the efficacy of lestaurtinib in this treatment setting.

As part of the UK AML15 (ISRCTN Registry Identifier: ISRCTN17161961) and AML17 trials (ISRCTN Registry Identifier: ISRCTN55675535), researchers enrolled 500 patients previously-untreated AML and confirmed FLT3-activating mutations who were mostly younger than 60 years. Of those, 74% had FLT3-ITD mutations, 23% had FLT3-TKD point mutations, and 2% had both types.

Participants were randomly assigned to receive 4 cycles of induction and consolidation chemotherapy with or without oral lestaurtinib, which was initiated 2 days after completing chemotherapy.

There was no significant difference in 5-year overall survival (hazard ratio, 0.90; 95% CI, 0.70-1.15; P = .3) or 5-year relapse-free survival (hazard ratio, 0.88; 95% CI, 0.69-1.12; P = .3) between the 2 treatment arms.

Exploratory subgroup analyses suggested that lestaurtinib may confer a survival advantage to patients receiving concomitant azole anti-fungal prophylactic therapy and gemtuzumab ozogamicin with the first course of chemotherapy.

RELATED: FDA Grants Priority Review to Midostaurin for Newly Diagnosed AML

Investigators also observed lower rates of relapse and improved overall survival among patients who achieved sustained levels of FLT3 inhibitory activity, potentially warranting continued evaluation of FLT3-directed therapy with first-line AML treatment.

Reference

  1. Knapper S, Russell N, Gilkes A, et al. A randomised assessment of adding the kinase inhibitor lestaurtinib to 1st-line chemotherapy for FLT3-mutated AML. Blood. 2016 Nov 21. doi: 10.1182/blood-2016-07-730648 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters